Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 11, 2005, Pages 1273-1280

  Agrawal, S ^a   Kaur, K J ^a   Singh, I ^a   Bhade, S ^a   Kaul, C L ^a   Panchagnula, Ramesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Bioequivalence; Fixed dose combination; Rifampicin; Sample size; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; HUMAN; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLE SIZE; SAMPLING; STATISTICAL ANALYSIS; WORLD HEALTH ORGANIZATION;

ANTIBIOTICS, ANTITUBERCULAR; DRUG COMBINATIONS; RIFAMPIN; SAMPLE SIZE; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 28444438937     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardized treatment regimens. Drugs 2003; 63: 535-553.
2. Norval P, Blomberg B, Kitler M, Dye C, Spinaci S. Estimate of the global market for rifampicin-containing fixed-dose combination tablets. Int J Tuberc Lung Dis 1999; 3: S292-S300.
3. Blomberg B, Evans P, Phanouvong S, Nunn P. Informal consultation on 4-drug fixed dose combinations (4FDCs) compliant with the WHO model list of essential drugs. 15-17 August 2001. WHO/CDS/TB/2002.299. Geneva, Switzerland: WHO, 2002.
4. Laing R, Fourie B, Ellard G, et al. Fixed-dose combination tablets for the treatment of tuberculosis. Report of an informal meeting held in Geneva Tuesday, 27 April 1999. WHO/CDS/CPC/TB/99.267. Geneva, Switzerland: WHO, 1999.
5. Panchagnula R, Agrawal S, Ashokraj Y, et al. Fixed dose combinations from tuberculosis: lessons learned from clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol 2004; 26: 703-721.
6. Anonymous. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Program of World Health Organization. Tubercle Lung Dis 1994; 75: 180-181.
7. World Health Organization. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchageability. Geneva, Switzerland: WHO, 1996.
8. Fourie B, Pillai G, Mclleron H, Smith P, Panchagnula R, Ellard G. Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to single drug reference preparations administered in loose combination (Model Protocol). WHO/CDS/TB/99.274. Geneva, Switzerland: WHO, 1999.
9. Government of India. Schedule Y: requirements and guidelines on clinical trials for import and manufacture of new drugs. In: Malik V, ed. The Drugs and Cosmetics Rules, 1945, Drugs (Price Control) Order, 1995 (As amended up to First Amendment of 1999), 12th ed. Lucknow, India: Eastern Book Company, 1999: pp 394-404.
10. Panchagnula R, Agrawal S, Kaul C L. Fixed dose combinations in the treatment of tuberculosis. Ind J Pharm Sci 2001; 63: 1-9.
11. Agrawal S, Kaur K J, Singh I, Bhade S R, Kaul C L, Panchagnula R. Determination of rifampicin bioequivalence in a three-drug FDC by WHO and Indian protocols: influence of sampling schedule and size. Int J Tuberc Lung Dis 2005; 9: 75-80.
12. Panchagnula R, Kaur K J, Singh I, Kaul C L. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S336-S342.
13. Panchagnula R, Kaur K J, Singh I, Kaul C L. Bioequivalence of rifampicin when administered as FDC formulations versus separate formulations. Meth Find Expt Clin Pharamcol 2000; 22: 689-694.
14. Agrawal S, Kaur K J, Singh I, Bhade S R, Kaul C L, Panchagnula R. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int J Phram 2002; 233: 169-177.
15. Agrawal S, Singh I, Kaur K J, Bhade S R, Kaul C L, Panchagnula R. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations at the same dose levels. Int J Clin Pharmacol Therp 2002; 40: 474-481.
16. Panchagnula R, Sood A, Sharda N, Kaur K J, Kaul C L. Analysis of rifampicin and its main metabolite in presence of pyrazinamide and isoniazid in plasma and urine samples by HPLC method. J Pharm Biomed Anal 1999; 18: 1505-1022.
17. Ritschel W A, Kearns G L. Handbook of basic pharmacokinetics including clinical applications. 5th ed. Washington, DC: American Pharmaceutical Association, 1999: pp 242-269, 296-303.
18. Hauschke D, Steinijans V W, Diletti E A. Distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990; 28: 72-78.
19. Bolton S. Sample size and power. In: Bolton S, ed. Pharmaceutical statistics: practical and clinical applications. 2nd ed. New York, NY: Marcel Dekker, Inc, 1990: pp 187-209.
20. Wang Y, Zhou S. Pilot trial for the assessment of relative bioavailability in generic drug product development: statistical power. J Biopharm Stat 1999; 9: 179-187.
21. McIlleron H, Gabriels G, Smith P J, Fourie P B, Ellard G A. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability. Int J Tuberc Lung Dis 1999; 3: S329-S335.
22. United States Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry. Statistical approaches to establishing bioequivalence. Washington, DC: FDA, January 2001.
23. European Agency for the Evaluation of Medicinal Products. Evaluations of Medicines for Human Use. Committee for Proprietary Medicinal Products (CPMP): Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98. July 2001. London, UK: EMEA, 2001. www.emea.eu.int/pdfs/ human/ewp/140188en.pdf Accessed August 2005.
24. Gallo G G, Radaelli P. Rifampicin. In: Florey K, ed. Analytical profiles of drug substances. London, UK: Academic Press, 1976: pp 467-513.
25. Ellard G A, Fourie P B. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int J Tuberc Lung Dis 1999; 3: S301-S308.
26. Tozer T N, Bois F Y, Walter W H, Chen M, Williams R L. Absorption rate vs. exposure: which is more useful for bioequivalence? Pharm Res 1996; 13: 453-456.
27. Farolfi M, Powers J D, Rescigno A. On the determination of bioequivalence. Pharmcol Res 1999; 39: 1-4.